Clinical Trial Update: Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

View source ↗

Summary

The pre-approval access program for talquetamab in relapsed or refractory multiple myeloma is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• Talquetamab (talquetamab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Relapsed or Refractory Multiple Myeloma | Status: NO_LONGER_AVAILABLE